Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04909398
Other study ID # P17-05
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 22, 2018
Est. completion date May 22, 2019

Study information

Verified date May 2021
Source Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The development of new oculometry techniques allows fine and dynamic measurements of pupillary diameter and use in routine clinical practice. The preliminary results obtained with innovative devices on healthy sjuets make it possible to envisage a clinical study on a population of patients suffering from retinal pathologies. This is a "proof of concept" study, which, if the expected results are confirmed, will make it possible to consider a study on a larger population, as well as the industrial development of a commercial device.


Description:

This is a single-head study that will take place at the National Ophthalmology Hospital Center (CHNO) and the Vision Institute (Streetlab) and the total duration of the study is 24 months . It is planned to include 60 participants divided into different groups: - 15 healthy subjects, called controls. - 15 patients with retinitis pigmentosa. - 15 patients with Leber's hereditary optic neuropathy. - 15 patients with Stargardt's disease. Patients will be pre-selected on files at the CHNO clinical investigation center based on the visual assessment carried out on the day of their arrival, the doctor may suggest that they participate in the study if the inclusion criteria are respected. The control subjects will be recruited thanks to the database of the Vision Institute at Streetlab.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date May 22, 2019
Est. primary completion date March 22, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Patients with an understanding of the French language to ensure a perfect understanding of the instructions during evaluations and documents relating to their involvement in the study. Visually impaired volunteers: Patients must have one of three conditions: Retinitis Pigmentosa, Stargardt disease, Leber optic neuropathy. Healthy volunteers: - Visual acuity of both corrected eyes (glasses) should be higher or equal 8/10th and a normal visual field. - Patients should not wear contact lenses (which may interfere with the recording of the pupil and eye movements) Exclusion Criteria: - Pregnant or lactating women will not be able to participate in this research. - Participants should not be unable to personally consent. - Subjects should not participate in another clinical trial that may interfere with this research. - Inability to personally consent. - Subjects should not present with degenerative diseases or any other disease that could interfere with the evaluations planned during this study. - The subject follows a drug treatment which can cause visual disturbances, changes in pupillary kinetics or cognitive disturbances. Secondary exclusion criteria (at the end of the inclusion visit): - Visually impaired subjects and controls for which calibration is not feasible. - Patients and control subjects having difficulty maintaining visual fixation. - Patients and subjects wearing corrective lenses making it impossible to record oculomotor activity with an infrared camera oculometer.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Dynamic pupillometry sessions
The evaluation protocol will include the following steps: Installation of the subject, adaptation of the chin rest for the best comfort of the participant Calibration of the oculometer consisting of ocular fixation of 9 fixation points distributed on the stimulation screen Final validation of the eligibility of the subject in the study according to the success or not of the calibration.

Locations

Country Name City State
France Centre Hospitalier National D'Ophtalùmologie des Quinze-Vingts Paris

Sponsors (2)

Lead Sponsor Collaborator
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts Streetlab

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dynamic pupillometry sessions pupillary reflex measurement Measurement of the right eye / left eye and binocular monocular pupillary reflex: pupillary response measured for 5 seconds with 3 levels of screen luminance, each stimulation will be separated from the next by a delay of 5 seconds Week 1
Primary RAPD measurement Alternate stimulation of the right and left eye: 10 repetitions, each corresponding to the stimulation of one eye for one second. Week 1
Primary Endogenous pupillary oscillation measurement Pupil oscillation frequency, for each eye and in binocular: during this test the participants observe the stimulation screen (central fixation point) for 45 seconds during which the lumnance of the screen is calculated to be proportional to the size of the pupil
in real time.
Week 1
Primary Measurement of pupillary activity by frequency marking This test consists of the simultaneous presentation of 5 areas of the screen, each of which is luminance modulated at a specific frequency. Week 1
Primary Pupillary measurement of color vision In this test, 2 background colors alternate at low frequency over time.
The physical luminance of one color is fixed while the other is adaptively changed during a test to reduce pupillary response.
Week 1
See also
  Status Clinical Trial Phase
Recruiting NCT01432847 - Cell Collection to Study Eye Diseases
Completed NCT04983914 - Retrospective NIS to Evaluate the Patient Benefit of TES
Recruiting NCT03845218 - Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
Completed NCT00231010 - Molecular Genetics of Retinal Degenerations
Active, not recruiting NCT04611503 - PDE6A Gene Therapy for Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT02909985 - Visual Activity Evoked by Infrared in Humans After Dark Adaptation N/A
Recruiting NCT01914913 - Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa Phase 1/Phase 2
Completed NCT01949623 - Biomarkers In Retinitis Pigmentosa (BIRP) N/A
Completed NCT01835002 - Transcorneal Electrical Stimulation - Multicenter Safety Study N/A
Completed NCT00407602 - Argus® II Retinal Stimulation System Feasibility Protocol N/A
Completed NCT00515814 - Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors N/A
Completed NCT00100230 - DHA and X-Linked Retinitis Pigmentosa Phase 2
Active, not recruiting NCT00378742 - Repository for Inherited Eye Diseases
Terminated NCT05085964 - An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa Phase 2
Recruiting NCT05805007 - Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa Early Phase 1
Recruiting NCT05909488 - Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II Phase 2/Phase 3
Recruiting NCT06291935 - Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene Phase 1
Recruiting NCT03078309 - The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients Early Phase 1
Completed NCT04238858 - Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa N/A
Active, not recruiting NCT01680510 - The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil Phase 1/Phase 2